HK1214758A1 - 用於治療多發硬化症的 受體調節劑 - Google Patents

用於治療多發硬化症的 受體調節劑

Info

Publication number
HK1214758A1
HK1214758A1 HK16102706.3A HK16102706A HK1214758A1 HK 1214758 A1 HK1214758 A1 HK 1214758A1 HK 16102706 A HK16102706 A HK 16102706A HK 1214758 A1 HK1214758 A1 HK 1214758A1
Authority
HK
Hong Kong
Prior art keywords
multiple sclerosis
receptor modulators
treating multiple
treating
modulators
Prior art date
Application number
HK16102706.3A
Other languages
English (en)
Inventor
Peter C Hiestand
Christian Schnell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1214758(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1214758A1 publication Critical patent/HK1214758A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
HK16102706.3A 2006-06-27 2014-05-02 用於治療多發硬化症的 受體調節劑 HK1214758A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612721.1A GB0612721D0 (en) 2006-06-27 2006-06-27 Organic compounds

Publications (1)

Publication Number Publication Date
HK1214758A1 true HK1214758A1 (zh) 2016-08-05

Family

ID=36888144

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102706.3A HK1214758A1 (zh) 2006-06-27 2014-05-02 用於治療多發硬化症的 受體調節劑

Country Status (21)

Country Link
US (3) US20100168078A1 (zh)
EP (4) EP2698154A1 (zh)
JP (7) JP2009541386A (zh)
KR (6) KR20150122812A (zh)
CN (2) CN103550195A (zh)
AU (7) AU2007264031C1 (zh)
BR (1) BRPI0713985A2 (zh)
CA (1) CA2653569C (zh)
DE (1) DE15177166T1 (zh)
DK (1) DK2959894T3 (zh)
ES (1) ES2887042T3 (zh)
GB (1) GB0612721D0 (zh)
HK (1) HK1214758A1 (zh)
HU (1) HUE059922T2 (zh)
LT (1) LT2959894T (zh)
MX (3) MX2008016133A (zh)
PL (1) PL2959894T3 (zh)
PT (1) PT2959894T (zh)
RU (1) RU2617502C2 (zh)
SI (1) SI2959894T1 (zh)
WO (1) WO2008000419A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
JP2010526116A (ja) * 2007-05-04 2010-07-29 ノバルティス アーゲー Ｓ１ｐ受容体調節因子の使用
KR20110020928A (ko) * 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
BRPI0916968A2 (pt) * 2008-08-18 2015-11-24 Novartis Ag compostos para o tratamento de neuropatias periféricas, formulações farmacêuticas compreendendo os referidos compostos, e usos dos mesmos
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
AR074694A1 (es) * 2008-12-18 2011-02-02 Novartis Ag Sal de hemifumarato del acido 1-(4-{1-[(e)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxilico, y otras formas cristalinas de la misma.
CA2746764A1 (en) * 2008-12-18 2010-06-24 Novartis Ag New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
ES2478842T3 (es) * 2008-12-18 2014-07-23 Novartis Ag Sal clorhidrato del ácido 1-(4-(1-((E)-4-ciclohexil-3-trifluorometil-benziloxiimino)-etil)-2-etil-benzil)-azetidina-3-carboxílico
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
NZ599966A (en) * 2009-11-24 2014-09-26 Allergan Inc Novel compounds as receptor modulators with therapeutic utility
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
CN102120720B (zh) * 2011-01-25 2013-05-22 上海华升生物科技有限公司 盐酸芬戈莫德的合成新方法
MX2014004813A (es) * 2011-10-21 2014-05-20 Novartis Ag Regimen de dosificacion para un modulador o agonista del receptor s1p.
BR112014022171B1 (pt) * 2012-03-23 2022-09-20 Nec Corporation Servidor de assinante doméstico, servidor de monitoramento, método executado por um servidor de assinante doméstico
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
CN105611917A (zh) * 2013-10-11 2016-05-25 帝国制药美国公司 局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP3400211A1 (en) 2016-01-04 2018-11-14 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
TW202131921A (zh) 2019-10-31 2021-09-01 瑞士商愛杜西亞製藥有限公司 Cxcr7拮抗劑與s1p1受體調節劑之組合
WO2023019320A1 (en) * 2021-08-20 2023-02-23 Carnegie Venture Capital Pty Ltd Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB612721A (en) 1946-02-11 1948-11-17 Richard William Bailey Improvements in combustion product power plant
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
RO119721B1 (ro) 1992-10-28 2005-02-28 Genentech Inc. Antagonişti ai factorului de creştere al celulelor vasculare endoteliale
DE69524962D1 (de) 1994-08-22 2002-02-14 Welfide Corp Benzolderivate und deren medizinische verwendung
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6214873B1 (en) 1997-04-04 2001-04-10 Welfide Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
JP4731016B2 (ja) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
ES2265929T3 (es) 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
AR025068A1 (es) 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6706731B2 (en) 2000-02-09 2004-03-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase
DE10033541C2 (de) 2000-07-11 2003-05-15 Litef Gmbh Lichtleitfaserspule für ein faseroptisches Sagnac-Interferometer und Verfahren zu ihrer Herstellung
IL153594A0 (en) 2000-07-13 2003-07-06 Sankyo Co Amino alcohol derivatives and pharmaceutical compositions containing the same
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
RU2199339C2 (ru) 2001-02-23 2003-02-27 Общество с ограниченной ответственностью "Биотех" Способ лечения рассеянного склероза
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
MXPA04011384A (es) * 2002-05-16 2005-02-14 Novartis Ag Uso de agentes de union del receptor edg en cancer.
CN100351244C (zh) * 2002-05-27 2007-11-28 诺瓦提斯公司 双芳族链烷醇
MXPA05003254A (es) * 2002-09-24 2005-06-08 Novartis Ag Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
KR20040048231A (ko) * 2002-12-02 2004-06-07 주식회사 두산 신생혈관생성 억제제 및 그를 포함한 암 치료용 키트
FR2848495B1 (fr) * 2002-12-12 2006-11-17 Sidel Sa Four pour chauffer au defile des ebauches de recipients en materiau thermoplastique
FR2854073B1 (fr) 2003-04-08 2008-03-14 Novartis Ag Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
MXPA05012461A (es) 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresores.
AU2004249664A1 (en) * 2003-05-19 2004-12-29 Irm Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
AU2005254058A1 (en) * 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for the treatment of human cancer
EP2377555A3 (en) * 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
PL1819326T3 (pl) * 2004-11-29 2014-12-31 Novartis Ag Schemat dawkowania agonisty receptora S1P
EP1824885A1 (en) * 2004-12-17 2007-08-29 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
RU2278687C1 (ru) 2005-06-16 2006-06-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" (ГОУ ВПО БГМУ РОСЗДРАВА РОССИИ) Способ лечения ремиттирующего рассеянного склероза
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
GB2527550B (en) 2014-06-25 2016-09-21 Cook Medical Technologies Llc Implantable medical device with lumen constriction

Also Published As

Publication number Publication date
ES2887042T1 (es) 2021-12-21
MX2022008950A (es) 2022-08-11
AU2007264031B2 (en) 2011-01-27
US8741963B2 (en) 2014-06-03
JP6931019B2 (ja) 2021-09-01
US9187405B2 (en) 2015-11-17
JP2021035955A (ja) 2021-03-04
CA2653569A1 (en) 2008-01-03
US20110237682A1 (en) 2011-09-29
MX2008016133A (es) 2009-01-15
AU2011201844B2 (en) 2012-10-25
AU2011201844A1 (en) 2011-05-19
AU2007264031A1 (en) 2008-01-03
JP7258832B2 (ja) 2023-04-17
JP2018109018A (ja) 2018-07-12
RU2617502C2 (ru) 2017-04-25
AU2021202395A1 (en) 2021-05-20
KR20210010956A (ko) 2021-01-28
EP2959894B1 (en) 2022-10-12
EP2037906A1 (en) 2009-03-25
BRPI0713985A2 (pt) 2012-11-20
AU2007264031C1 (en) 2016-12-15
DK2959894T1 (da) 2021-12-20
MX2019012750A (es) 2020-02-03
JP2009541386A (ja) 2009-11-26
AU2013200356A1 (en) 2013-02-14
CN101478961B (zh) 2013-11-27
EP3797765A1 (en) 2021-03-31
AU2013200356B2 (en) 2016-09-29
AU2018202210A1 (en) 2018-04-26
CN101478961A (zh) 2009-07-08
ES2887042T3 (es) 2022-11-14
GB0612721D0 (en) 2006-08-09
SI2959894T1 (sl) 2022-11-30
DK2959894T3 (da) 2022-10-17
RU2013131176A (ru) 2015-01-20
DE15177166T1 (de) 2022-01-27
KR20150122812A (ko) 2015-11-02
EP2698154A1 (en) 2014-02-19
US20140228446A1 (en) 2014-08-14
HUE15177166T1 (hu) 2022-05-28
KR20090024281A (ko) 2009-03-06
HUE059922T2 (hu) 2023-01-28
LT2959894T (lt) 2022-11-10
PL15177166T1 (pl) 2022-03-07
CA2653569C (en) 2016-06-21
KR20140069178A (ko) 2014-06-09
AU2016266058A1 (en) 2016-12-22
JP2019167352A (ja) 2019-10-03
RU2569732C2 (ru) 2015-11-27
JP2016185957A (ja) 2016-10-27
KR20170138583A (ko) 2017-12-15
PL2959894T3 (pl) 2022-11-14
JP2023098949A (ja) 2023-07-11
PT2959894T (pt) 2022-10-18
RU2009102278A (ru) 2010-08-10
EP2959894A1 (en) 2015-12-30
US20100168078A1 (en) 2010-07-01
WO2008000419A1 (en) 2008-01-03
JP2013166761A (ja) 2013-08-29
KR20190030776A (ko) 2019-03-22
AU2019219818A1 (en) 2019-09-12
CN103550195A (zh) 2014-02-05

Similar Documents

Publication Publication Date Title
HK1214758A1 (zh) 用於治療多發硬化症的 受體調節劑
HK1225620A1 (zh) 改善的神經再生的補充抑制
EP2079414A4 (en) SYSTEM FOR CHEMOHYPER THERMAL TREATMENT
IL193639A0 (en) Collagenase for treating cellulite
EP2344446A4 (en) S1P RECEPTOR MODULATORS
IL197818A0 (en) Multiple sclerosis therapy
PL2487231T3 (pl) Środek do obróbki twardych powierzchni
IL198990A0 (en) Cb1 receptor modulators
IL198352A0 (en) Modulators of neuronal regeneration
PT2205720T (pt) Composições para tratamento de esclerose múltipla
IL204786A0 (en) Benzyl - cycloalkyl sphingosing 1 - phosphate receptor modulators
GB0701992D0 (en) Grehlin Receptor Modulators
IL206192A0 (en) Modulators of neuronal regeneration
EP2087129A4 (en) METHOD FOR IDENTIFYING MODULATORS OF THE NRF2-KEAP1-ARE PATH
PL2043792T3 (pl) System do obróbki ciągłej
ZA200806237B (en) Cannibinoid receptor modulators
ZA200901672B (en) Compounds for treating proliferative disorders
GB0722340D0 (en) Sphingosine-1-phosphate (S1P) receptor compounds
ZA200904663B (en) CB1 receptor modulators
GB0614058D0 (en) Treatment for multiple sclerosis
ZA200902586B (en) Modulators of neuronal regeneration
AU2007906261A0 (en) Therapy for multiple sclerosis
GB0607351D0 (en) Apparatus for breathalysing
GB0605203D0 (en) Composition for treating a skin disorder
GB0625695D0 (en) Holographic apparatus